Abstract 1480P
Background
Excess body weight induces a meta-inflammatory state defined by chronic low-grade systemic innate immune activation mediated by increased proinflammatory cytokines. We previously showed a negative association between baseline circulating IL8/IL6 and overall survival (OS)/progression free survival (PFS) in NIVO-treated mRCC. (Carril-Ajuria.ASCO.2022). We evaluated the impact of the baseline levels of circulating cytokines according to BMI on clinical outcomes in mRCC pts treated with nivolumab within the NIVOREN trial.
Methods
Clinicopathologic and survival data was collected of mRCC pts treated with NIVO within the GETUG-AFU26 NIVOREN trial (NCT0301335). Patients were clasified according to BMI (kg/m2): underweight/normal weight (BMI ≤ 24.9), overweight (25 ≤ BMI ≤ 29.9) and obese (BMI ≥ 30). A panel of 7 cytokines was analyzed for each plasma sample using the MSD assay. The association between BMI (n=708) PFS/OS) was analyzed.
Results
Of the 708 pts included in the analysis, half were overweight (n=255; 36%) and obese (n=111; 16%). Median age was 64 years; Karnofsky performance status (KPS) was ≥80% in 81%. Obese pts had a lower proportion of sarcomatoid features (5% vs ≈8%) and poor-risk IMDC (14% vs ≈27%). IL8 (n=345) was significantly higher in overweight/obese pts (p<0.05). No significant differences in IL6, IL7, VCAM 1, VEGF, BCA, BAFF or 4-1BB according to BMI were found. After a median follow-up of 23.9 months (mo), underweight/normal, overweight, and obese pts had a 12-mo PFS of 20%, 24%, and 34% (p<0.01) and the 12-mo OS of underweight/normal, overweight, and obese pts was.
Conclusions
The obesity paradox may still be considered among mRCC pts treated with nivolumab, although our findings were not statistically significant after MVA. Plasma concentration of IL8 was significantly higher in overweight/obese patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Colomba: Financial Interests, Personal, Invited Speaker: Ipsen. S. Negrier: Financial Interests, Institutional, Invited Speaker: Ipsen; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Invited Speaker: Janssen. C.M. Chevreau: Financial Interests, Personal, Invited Speaker: Sanofi, Janssen; Other, Personal, Invited Speaker: Ipsen. G. Gravis Mescam: Financial Interests, Institutional, Invited Speaker: Ipsen, MSD; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Institutional, Principal Investigator: BMS. S. Oudard: Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Institutional, Advisory Board: Ipsen, Janssen. B. Laguerre: Financial Interests, Institutional, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: BMS. P. Barthelemy: Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Institutional, Principal Investigator: MSD, Janssen. M. Gross Goupil: Financial Interests, Personal, Invited Speaker: Sanofi, Janssen; Financial Interests, Institutional, Advisory Board: Ipsen; Financial Interests, Institutional, Principal Investigator: MSD; Financial Interests, Personal, Advisory Board: BMS. A. Thiery-Vuillemin: Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Institutional, Principal Investigator: Pfizer, MSD; Financial Interests, Personal, Advisory Board: Janssen. F. Joly Lobbedez: Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Institutional, Invited Speaker: Ipsen; Financial Interests, Institutional, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: Eisai. S. Ladoire: Financial Interests, Institutional, Invited Speaker: Ipsen, Janssen. B. Escudier: Financial Interests, Institutional, Principal Investigator: BMS; Financial Interests, Personal, Invited Speaker: Ipsen, BMS; Financial Interests, Institutional, Advisory Board: Pfizer. L. Albiges: Financial Interests, Institutional, Principal Investigator: MSD; Financial Interests, Institutional, Invited Speaker: Ipsen, BMS; Financial Interests, Personal, Speaker’s Bureau: Pfizer. All other authors have declared no conflicts of interest.